Literature DB >> 17804652

Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile.

Megan E Reller1, Clara A Lema, Trish M Perl, Mian Cai, Tracy L Ross, Kathleen A Speck, Karen C Carroll.   

Abstract

We examined the incremental yield of stool culture (with toxin testing on isolates) versus our two-step algorithm for optimal detection of toxigenic Clostridium difficile. Per the two-step algorithm, stools were screened for C. difficile-associated glutamate dehydrogenase (GDH) antigen and, if positive, tested for toxin by a direct (stool) cell culture cytotoxicity neutralization assay (CCNA). In parallel, stools were cultured for C. difficile and tested for toxin by both indirect (isolate) CCNA and conventional PCR if the direct CCNA was negative. The "gold standard" for toxigenic C. difficile was detection of C. difficile by the GDH screen or by culture and toxin production by direct or indirect CCNA. We tested 439 specimens from 439 patients. GDH screening detected all culture-positive specimens. The sensitivity of the two-step algorithm was 77% (95% confidence interval [CI], 70 to 84%), and that of culture was 87% (95% CI, 80 to 92%). PCR results correlated completely with those of CCNA testing on isolates (29/29 positive and 32/32 negative, respectively). We conclude that GDH is an excellent screening test and that culture with isolate CCNA testing detects an additional 23% of toxigenic C. difficile missed by direct CCNA. Since culture is tedious and also detects nontoxigenic C. difficile, we conclude that culture is most useful (i) when the direct CCNA is negative but a high clinical suspicion of toxigenic C. difficile remains, (ii) in the evaluation of new diagnostic tests for toxigenic C. difficile (where the best reference standard is essential), and (iii) in epidemiologic studies (where the availability of an isolate allows for strain typing and antimicrobial susceptibility testing).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804652      PMCID: PMC2168505          DOI: 10.1128/JCM.01305-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

Review 2.  Clinical manifestations, treatment and control of infections caused by Clostridium difficile.

Authors:  E Bouza; P Muñoz; R Alonso
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

3.  A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

Authors:  M Catherine McEllistrem; Robert J Carman; Dale N Gerding; C W Genheimer; L Zheng
Journal:  Clin Infect Dis       Date:  2004-12-15       Impact factor: 9.079

4.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

Review 5.  Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture.

Authors:  Michel Delmée; Johan Van Broeck; Anne Simon; Michèle Janssens; Véronique Avesani
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

6.  Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains.

Authors:  Frédéric Barbut; Dominique Decré; Valérie Lalande; Béatrice Burghoffer; Latifa Noussair; Anne Gigandon; Florence Espinasse; Laurent Raskine; Jérome Robert; Alain Mangeol; Catherine Branger; Jean-Claude Petit
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Cytotoxicity and antimicrobial susceptibility of Clostridium difficile isolated from hospitalized children with acute diarrhea.

Authors:  Claudia Elisa Alves Ferreira; Viviane Nakano; Mario Julio Avila-Campos
Journal:  Anaerobe       Date:  2004-06       Impact factor: 3.331

9.  Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping.

Authors:  Renate J van den Berg; Eric C J Claas; Duddy H Oyib; Corné H W Klaassen; Lenie Dijkshoorn; Jon S Brazier; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

10.  Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with Clostridium difficile disease.

Authors:  Scott D Lee; David K Turgeon; Cynthia W Ko; Thomas R Fritsche; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2003-07       Impact factor: 10.864

View more
  56 in total

1.  Laboratory diagnosis of Clostridium difficile infection.

Authors:  S D Goldenberg; P R Cliff; G L French
Journal:  J Clin Microbiol       Date:  2010-08       Impact factor: 5.948

2.  Diagnostic algorithm using a sensitive broth culture method for detection of Clostridium difficile toxin from stool samples.

Authors:  Paul Bayardelle
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system.

Authors:  Alex B Ryder; Ying Huang; Haijing Li; Min Zheng; Xiaobo Wang; Charles W Stratton; Xiao Xu; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

4.  A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.

Authors:  J Michael Miller; Matthew J Binnicker; Sheldon Campbell; Karen C Carroll; Kimberle C Chapin; Peter H Gilligan; Mark D Gonzalez; Robert C Jerris; Sue C Kehl; Robin Patel; Bobbi S Pritt; Sandra S Richter; Barbara Robinson-Dunn; Joseph D Schwartzman; James W Snyder; Sam Telford; Elitza S Theel; Richard B Thomson; Melvin P Weinstein; Joseph D Yao
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

5.  Evaluation of diagnostic tests for Clostridium difficile infection.

Authors:  Jonathan Swindells; Nigel Brenwald; Nathan Reading; Beryl Oppenheim
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948

6.  C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens.

Authors:  Criziel D Quinn; Susan E Sefers; Wisal Babiker; Ying He; Romina Alcabasa; Charles W Stratton; Karen C Carroll; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

Review 7.  Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?

Authors:  Fred C Tenover; Ellen Jo Baron; Lance R Peterson; David H Persing
Journal:  J Mol Diagn       Date:  2011-08-18       Impact factor: 5.568

8.  Modifications of commercial toxigenic Clostridium difficile PCR resulting in improved economy and workflow efficiency.

Authors:  Erik Munson; Dorothy Bilbo; Mary Paul; Maureen Napierala; Jeanne E Hryciuk
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 9.  A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics.

Authors:  John D Perry
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

10.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.